2024 ASCO Annual Meeting

May 31 – June 4 | Booth #34157 | Chicago, IL

May 31 – June 4 | Booth #34157 | Chicago, IL

Headed to the 2024 ASCO Annual Meeting?

Meet Our Experts at Booth #34157

The oncology community will be at the 2024 ASCO Annual Meeting, May 31 – June 4, 2024 in Chicago, Illinois.

Stop by booth #34157 to connect with our oncology clinical development experts. Our dedicated team will be there to discuss how to support your upcoming study from trial design and delivery to commercial optimization. Request a meeting to discuss your specific challenges or learn how we can help make intelligent connections to accelerate oncology clinical breakthroughs.

Attending Team:

Lyon Gleich, MD
Senior Vice President, Hematology & Oncology

Blythe Thomson, MD
Senior Vice President, Hematology & Oncology

Gaston Demonty, MD
Senior Medical Director, Hematology & Oncology

Greg Hale, MD, FAACP
Senior Medical Director, Hematology & Oncology

Amanda Goldrick, MD
Medical Director, Hematology & Oncology

Mehdi Adineh, PhD
Vice President,
Medpace Core Labs

Scott Holland, PhD
Sr. Director, Scientific Affairs Medpace Core Labs

How to Attend the 2024 ASCO Annual Meeting

For more information about ASCO, please visit the official 2024 ASCO Annual Meeting website.

Request a Meeting at ASCO

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

An Integrated Approach to Global Clinical Research

Your oncology breakthrough starts here

Through our proven full-service outsourcing model, Medpace consistently delivers high-quality results, showcasing profound expertise in managing Phase I-IV trials. Operating in over 40 countries, we have earned a reputation for taking on some of the most complex and challenging cancer research studies.

  • Led by a team of medical, operational, and regulatory experts experienced in hematology and oncology
  • Integrated services and systems through out wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab, and Phase I Unit, in addition to our Clinical Trial Management System
  • Preferred provider relationships with key sites, expediting site start-up, enhancing recruitment, and maximizing trial efficacy
  • Experience in targeted, advanced, and radiation therapies